GR3005191T3 - - Google Patents

Info

Publication number
GR3005191T3
GR3005191T3 GR910402234T GR910402234T GR3005191T3 GR 3005191 T3 GR3005191 T3 GR 3005191T3 GR 910402234 T GR910402234 T GR 910402234T GR 910402234 T GR910402234 T GR 910402234T GR 3005191 T3 GR3005191 T3 GR 3005191T3
Authority
GR
Greece
Prior art keywords
controlled release
matrix
contain
release matrix
carboxyalkylcellulose
Prior art date
Application number
GR910402234T
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GR3005191T3 publication Critical patent/GR3005191T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GR910402234T 1986-06-05 1992-07-16 GR3005191T3 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868613689A GB8613689D0 (en) 1986-06-05 1986-06-05 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
GR3005191T3 true GR3005191T3 (el) 1993-05-24

Family

ID=10598992

Family Applications (1)

Application Number Title Priority Date Filing Date
GR910402234T GR3005191T3 (el) 1986-06-05 1992-07-16

Country Status (15)

Country Link
US (1) US4828836A (el)
EP (1) EP0248548B1 (el)
JP (1) JPH0780787B2 (el)
KR (1) KR890004688B1 (el)
AT (1) ATE77943T1 (el)
AU (1) AU602337B2 (el)
CA (1) CA1297017C (el)
DE (1) DE3780222T2 (el)
DK (1) DK289387A (el)
ES (1) ES2042561T3 (el)
FI (1) FI92014C (el)
GB (1) GB8613689D0 (el)
GR (1) GR3005191T3 (el)
IE (1) IE60757B1 (el)
ZA (1) ZA873735B (el)

Families Citing this family (175)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5069911A (en) * 1985-02-05 1991-12-03 Sandoz Ltd. Pharmaceutical 9,10-dihydrogenated ergot alkaloid containing compositions
DE3636123A1 (de) * 1986-10-23 1988-05-05 Rentschler Arzneimittel Arzneizubereitungen zur oralen verabreichung, die als einzeldosis 10 bis 240 mg dihydropyridin enthalten
FR2618073B1 (fr) * 1987-07-16 1990-09-07 Pf Medicament Comprimes de type a matrice hydrophile a base de salbutamol et leur procede de preparation
US4994276A (en) * 1988-09-19 1991-02-19 Edward Mendell Co., Inc. Directly compressible sustained release excipient
US5364622A (en) * 1987-12-04 1994-11-15 Dr. Karl Thomae Gmbh Methods for preventing adhesions to organs and parts of organs by application of tissue plasminogen activator and hydroxyethylcellulose hydrogel
DE3741149A1 (de) * 1987-12-04 1989-06-15 Thomae Gmbh Dr K Zubereitungsformen zur verhinderung von adhaesionen von organen und organteilen
US5055300A (en) * 1988-06-17 1991-10-08 Basic Bio Systems, Inc. Time release protein
US5079005A (en) * 1988-06-17 1992-01-07 Gupta Kashmiri L Time release protein
US5023080A (en) * 1988-06-17 1991-06-11 Basic Bio Systems, Inc. Time release protein
US5135757A (en) * 1988-09-19 1992-08-04 Edward Mendell Co., Inc. Compressible sustained release solid dosage forms
US5169639A (en) * 1988-09-19 1992-12-08 Edward Mendell Co., Inc. Controlled release verapamil tablets
HU203041B (en) * 1989-03-14 1991-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin
US5275823A (en) * 1989-04-27 1994-01-04 Smith Kline & French Laboratories Ltd. Pharmaceutical compositions
ES2082174T3 (es) * 1990-04-09 1996-03-16 Pfizer Comprimido prensado de reducidas calorias con sabor perfeccionado.
US5403593A (en) * 1991-03-04 1995-04-04 Sandoz Ltd. Melt granulated compositions for preparing sustained release dosage forms
US5221698A (en) * 1991-06-27 1993-06-22 The Regents Of The University Of Michigan Bioactive composition
US5225201A (en) * 1991-08-23 1993-07-06 Minnesota Mining And Manufacturing Company Salsalate tablet
FI93924C (fi) * 1991-09-17 1995-06-26 Martti Lauri Antero Marvola Menetelmä säädellysti lääkeainetta vapauttavan valmisteen valmistamiseksi
CA2082185C (en) * 1991-11-26 2004-01-20 Alexander R. Pokora Protease catalyzed treatments of lignocellulose materials
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
GB9200607D0 (en) * 1992-01-13 1992-03-11 Ethical Pharma Ltd Pharmaceutical compositions containing nifedipine and process for the preparation thereof
US5472711A (en) * 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
USRE39300E1 (en) 1993-01-28 2006-09-19 Virginia Commonwealth University Medical College Of Virginia Inhibiting the development of tolerance to and/or dependence on an addictive substance
IL119660A (en) * 1993-05-10 2002-09-12 Euro Celtique Sa Controlled release formulation comprising tramadol
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6676967B1 (en) * 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US20060263428A1 (en) * 1993-09-20 2006-11-23 Eugenio Cefali Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US20020006438A1 (en) * 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5744164A (en) * 1994-12-16 1998-04-28 Nestec S.A. Sustained release microparticulate caffeine formulation
EP0742008A1 (en) * 1995-05-11 1996-11-13 Euro-Celtique S.A. Controlled release pharmaceutical formulations
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
IT1276130B1 (it) 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
US20060068001A1 (en) * 1996-03-25 2006-03-30 Wyeth Extended release formulation
SE9704401D0 (sv) * 1997-11-28 1997-11-28 Astra Ab Matrix pellets for greasy, oily or sticky drug substances
TR200001828T2 (tr) * 1997-12-22 2000-11-21 Euro-Celtique, S.A. Opioid dozaj şekillerinin kötüye kullanımını önlemeye yönelik bir yöntem.
SI1685839T1 (sl) 1997-12-22 2013-08-30 Euro-Celtique S.A. Farmacevtska oralna dozirna oblika, ki vsebuje kombinacijo opioidnega agonista in opioidnega antagonista
JP4523153B2 (ja) 1998-03-19 2010-08-11 ブリストル−マイヤーズ スクイブ カンパニー 易溶性薬物の二層性放出制御送達システムおよび方法
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US6673367B1 (en) * 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6878749B2 (en) * 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
US7537785B2 (en) * 1999-10-29 2009-05-26 Nitromed, Inc. Composition for treating vascular diseases characterized by nitric oxide insufficiency
ES2374717T3 (es) 1999-10-29 2012-02-21 Euro-Celtique S.A. Formulaciones de hidrocodona de liberación controlada.
EP1244455B1 (en) 1999-10-29 2009-07-22 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US7771746B2 (en) * 1999-12-03 2010-08-10 Polichem Sa Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof
NZ520554A (en) * 2000-02-08 2005-08-26 Euro Celtique S Tamper-resistant oral opioid agonist formulations
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6855721B1 (en) 2000-07-28 2005-02-15 Indevus Pharmaceuticals, Inc. Methods and compositions for alleviating stuttering
SE0003125D0 (sv) * 2000-09-05 2000-09-05 Astrazeneca Ab Modified polymers
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
JP2004512354A (ja) 2000-10-30 2004-04-22 ユーロ−セルティーク，エス．エイ． ヒドロコドン放出制御製剤
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
CN1525851A (zh) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
DK1416842T3 (da) * 2001-07-18 2009-03-16 Euro Celtique Sa Farmaceutiske kombinationer af oxycodon og naloxon
DE60231507D1 (de) * 2001-07-20 2010-07-01 Psychogenics Inc Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
DE60232417D1 (de) 2001-08-06 2009-07-02 Euro Celtique Sa Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
US20030157168A1 (en) * 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
KR20040098050A (ko) 2002-04-05 2004-11-18 유로-셀띠끄 소시에떼 아노님 옥시코돈 및 날록손을 포함하는 약제학적 제제
AU2003301808A1 (en) * 2002-05-13 2004-06-07 Endo Pharmaceuticals Inc. Abuse-resistant opioid dosage form
AU2003234395B2 (en) * 2002-05-13 2008-01-24 Endo Pharmaceuticals Inc. Abuse-resistant opioid solid dosage form
KR100897890B1 (ko) 2002-06-17 2009-05-18 인벤티아 헬스케어 피브이티. 엘티디. 티아졸리딘디온 및 바이구아나이드를 함유하는 다층 정제및 그의 제조 방법
US7214387B2 (en) * 2002-08-02 2007-05-08 Penwest Pharmaceuticals Company Sustained release formulations of metformin
PT1551372T (pt) * 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc Subunidade de sequestração e composições e métodos relacionados
US20040086566A1 (en) * 2002-11-04 2004-05-06 Alpharma, Inc. Waxy matrix dosage forms
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
TWI347201B (en) * 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
PT2316456T (pt) 2003-04-29 2017-09-05 Orexigen Therapeutics Inc Composições para afetar a perda de peso compreendendo naltrexona e bupropion
US20050042289A1 (en) * 2003-04-29 2005-02-24 Yamanouchi Pharma Technologies, Inc. Tablets and methods for modified release of hydrophylic and other active agents
BR0302017B1 (pt) 2003-06-02 2014-10-29 Ems Sigma Pharma Ltda Composição farmacêutica sublingual a base de um agonista do receptor central de benzodiazepínicos
AU2004258949B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
CA2533292C (en) 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
EP1648418A4 (en) 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
CA2535177A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
EP1653924A4 (en) 2003-08-12 2009-09-09 Middlebrook Pharmaceuticals In ANTIBIOTICS, USE AND FORMULATION ASSOCIATED
CA2535780A1 (en) 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
US8460710B2 (en) 2003-09-15 2013-06-11 Shionogi, Inc. Antibiotic product, use and formulation thereof
US7410978B2 (en) * 2003-11-04 2008-08-12 Supernus Pharmaceuticals, Inc. Once daily dosage forms of trospium
JP4771956B2 (ja) 2003-11-04 2011-09-14 スパーナス ファーマシューティカルズ インコーポレイテッド バイオアベイラビリティーエンハンサを含む第四級アンモニウム化合物の組成物
US20050202079A1 (en) * 2004-03-15 2005-09-15 Mylan Pharmaceuticals Inc. Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation
AU2005237607B2 (en) 2004-04-27 2010-12-16 Medicinova, Inc. Phenoxyalkycarboxylic acid derivatives in the treatment of inflammatory diseases
EP1750710B1 (en) * 2004-05-14 2014-04-16 KNU-Industry Cooperation Foundation Neuroprotective properties of dextrorotatory morphinans
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
CA2572292A1 (en) 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
FR2875409B1 (fr) * 2004-09-17 2010-05-07 Sanofi Aventis Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
WO2006058236A2 (en) 2004-11-24 2006-06-01 Neuromolecular Pharmaceuticals, Inc. Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
EP1702558A1 (en) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
RU2408368C2 (ru) 2005-06-27 2011-01-10 Биовэйл Лэборэториз Интернэшнл С.Р.Л. Препараты соли бупропиона с модифицированным высвобождением
WO2007056205A2 (en) * 2005-11-04 2007-05-18 Eastman Chemical Company Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents
JP5180092B2 (ja) 2005-11-22 2013-04-10 オレキシジェン・セラピューティクス・インコーポレーテッド インスリン感受性を増すための組成物および方法
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US8299052B2 (en) * 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US20070281017A1 (en) * 2006-06-06 2007-12-06 Endo Pharmaceuticals Inc., A Delaware Corporation Sustained release oxycodone composition with acrylic polymer and metal hydroxide
US8158156B2 (en) * 2006-06-19 2012-04-17 Alpharma Pharmaceuticals, Llc Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
AU2007275033A1 (en) * 2006-07-21 2008-01-24 Lab International Srl Hydrophobic abuse deterrent delivery system
AU2007319472B2 (en) 2006-11-09 2013-01-17 Nalpropion Pharmaceuticals Llc Methods Of Administering Weight Loss Medications
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US20090246276A1 (en) 2008-01-28 2009-10-01 Graham Jackson Pharmaceutical Compositions
MX2010012909A (es) 2008-05-30 2011-02-25 Orexigen Therapeutics Inc Metodos para tratamiento de condiciones de grasa visceral.
CA2730211C (en) * 2008-07-07 2016-11-08 Euro-Celtique S.A. Use of opioid antagonists for treating urinary retention
WO2010020321A1 (en) 2008-08-20 2010-02-25 Cargill, Incorporated New polydextrose material
EP2405915B1 (en) 2009-03-10 2018-10-24 Euro-Celtique S.A. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US10525152B2 (en) 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
MX365650B (es) * 2009-12-02 2019-06-10 Adamas Pharmaceuticals Inc Composiciones de amantadina y metodos para su uso.
EP3659604A1 (en) 2010-01-11 2020-06-03 Nalpropion Pharmaceuticals, Inc. Methods of providing weight loss therapy in patients with major depression
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
US8835499B2 (en) 2011-12-08 2014-09-16 Medicinova, Inc. Method of treating non-alcoholic fatty liver disease and steatohepatitis
US8962687B2 (en) 2012-12-05 2015-02-24 Medicinova, Inc. Method of treating liver disorders
EP2819706A4 (en) 2012-02-29 2015-08-12 Univ Hospitals Cleveland Medical Ct TARGETED TREATMENT OF ANAEROBIC CANCER
HUE049859T2 (hu) 2012-06-06 2020-10-28 Nalpropion Pharmaceuticals Llc Készítmény magas kardiovaszkuláris kockázatnak kitett páciensekben túlsúly és elhízás kezelésére szolgáló eljárásban történõ alkalmazásra
US20150133664A1 (en) 2012-06-07 2015-05-14 Board Of Regents, The University Of Texas System Chemical transformations of (-)-codeine to afford derivatives of codeine and morphine thereof
BR112015003733A2 (pt) * 2012-08-23 2017-07-04 Cardiolynx Ag composições de liberação estendida de um nitrato de aminoalquila
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
NZ716267A (en) 2013-07-23 2017-05-26 Euro Celtique Sa A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
WO2015013395A1 (en) 2013-07-25 2015-01-29 Medicinova, Inc. Methods for reducing triglyceride, total cholesterol and low density lipoprotein blood levels
EP3068880A4 (en) 2013-11-11 2017-06-14 University Hospitals Cleveland Medical Center Targeted treatment of anerobic cancer
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
US9346754B2 (en) 2014-05-08 2016-05-24 Medicinova, Inc. Method of treating advanced non-alcoholic steatohepatitis
US20150321989A1 (en) 2014-05-08 2015-11-12 Medicinova, Inc. Method of treating idiopathic pulmonary fibrosis
JP6469727B2 (ja) 2014-06-02 2019-02-13 メディシノバ・インコーポレイテッドＭｅｄｉｃｉＮｏｖａ， Ｉｎｃ． 線維症の抑制又は治療方法
CA2936741C (en) 2014-10-31 2018-11-06 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
ES2891306T3 (es) 2014-11-26 2022-01-27 Medicinova Inc Combinación de ibudilast y riluzol y métodos de utilización de los mismos
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
JP2019519487A (ja) 2016-05-05 2019-07-11 アクエスティブ セラピューティクス インコーポレイテッド 送達増強エピネフリン組成物
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
AU2018360383A1 (en) 2017-11-02 2020-05-21 Natureceuticals Sdn. Bhd. Extract of orthosiphon stamineus, formulations, and uses thereof
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US20220088037A1 (en) * 2018-12-18 2022-03-24 DDP Specialty Electronic Materials US, Inc. A sustained release composition comprising a hydroxyalkyl methylcellulose
CA3217719A1 (en) 2021-05-28 2022-12-01 Kazuko Matsuda Phenoxyalkylcarboxylic acid derivatives and their use in lowering triglyceride levels

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3766165A (en) * 1966-08-17 1973-10-16 Pfizer Polysaccharides and their preparation
US4327077A (en) * 1981-05-29 1982-04-27 Life Savers, Inc. Compressed chewable antacid tablet and method for forming same
US4459280A (en) * 1982-07-23 1984-07-10 G. D. Searle & Co. Psyllium hydrophilic mucilloid composition
US4548806A (en) * 1982-07-23 1985-10-22 G. D. Searle & Co. Psyllium hydrophilic mucilloid composition
US4698264A (en) * 1982-08-02 1987-10-06 Durkee Industrial Foods, Corp. Particulate composition and process for making same
US4576818A (en) * 1984-08-07 1986-03-18 Euroceltique, S.A. Iodophor composition
US4668510A (en) * 1984-08-07 1987-05-26 Euroceltique, S.A. Iodophor composition

Also Published As

Publication number Publication date
ZA873735B (en) 1987-11-23
EP0248548A3 (en) 1988-03-30
DE3780222T2 (de) 1993-02-25
JPS62292732A (ja) 1987-12-19
ATE77943T1 (de) 1992-07-15
FI92014C (fi) 1994-09-26
EP0248548B1 (en) 1992-07-08
DK289387A (da) 1987-12-06
IE871480L (en) 1987-12-05
GB8613689D0 (en) 1986-07-09
AU602337B2 (en) 1990-10-11
DK289387D0 (da) 1987-06-04
JPH0780787B2 (ja) 1995-08-30
AU7378787A (en) 1987-12-10
CA1297017C (en) 1992-03-10
EP0248548A2 (en) 1987-12-09
IE60757B1 (en) 1994-08-10
ES2042561T3 (es) 1993-12-16
FI872481A (fi) 1987-12-06
FI872481A0 (fi) 1987-06-03
DE3780222D1 (de) 1992-08-13
KR890004688B1 (ko) 1989-11-25
KR880000089A (ko) 1988-03-23
US4828836A (en) 1989-05-09
FI92014B (fi) 1994-06-15

Similar Documents

Publication Publication Date Title
GR3005191T3 (el)
ES2186715T3 (es) Uso de un tensioactivo lipofilico en una composicion farmaceutica.
ES2032397T3 (es) Procedimiento para preparar una composicion en dispersion solida de la sustancia fr-900506
IT8319295A0 (it) Schiume di alcooli altamente stabili e procedimenti di preparazione e di impiego di tali schiume.
NL300136I1 (nl) Farmacologisch actieve catecholderivaten en samenstellingen ervan.
CA2027592A1 (en) Solid pharmaceutical preparations of active form of vitamin d_ of improved stability
FI875272A (fi) Baerarloesningsmedelssystem i tvao fas.
GR3030732T3 (en) Pharmaceutical compositions including a drug, a cross-linked polymeric substance, an oil, and a surface active agent.
HU9200249D0 (en) Veterinary product with delayed active agent activity
NL193907B (nl) Basische ether en farmaceutische samenstelling die de basische ether als actief bestanddeel bevat.
IT8820073A0 (it) Formulazioni farmaceutiche acquose di piroxicam e procedimento per laloro preparazione.
DE68904147D1 (de) Kronenetherverbindung und trennmittel.
SE8401538D0 (sv) Forbettrade analgetiska och anti-inflammatoriska kompositioner innefattande koffein och forfaranden for anvendning av dessa
IT9021370A0 (it) Composizioni farmaceutiche con migliorate proprieta' di dissoluzione.
IT8722264A0 (it) Procedimento per la preparazione di compresse solubili e/o divisibili e compresse cosi' ottenute.
DE69012031D1 (de) Optisch aktive Benzylalkoholverbindung und pharmazeutische Zusammensetzung.
ATE70445T1 (de) Pharmazeutische praeparate.
FR2701847B1 (fr) Compositions pharmaceutiques et cosmétiques à base d'albumine végétale, préparations contenant de telles compositions et procédé de préparation.
ATE60231T1 (de) Unloesliches arzneimittel das lokal im ohr verabreicht wird.
HUT61561A (en) Process for producing octadecyl-/2-(n-methylpiperidino)-ethyl/-phosphate and pharmaceutical compositions comprising same as active ingredient
NL193441B (nl) Farmaceutisch preparaat voor veterinair gebruik.
DE3871159D1 (de) Pharmazeutische und tieraerztliche zusammensetzungen.
EP0348664A3 (en) Pharmaceutical compositions containing monoacetoacetins for treating tumours
FI920222A0 (fi) Doseringsmedel innefattande en jonofor.
HUT43235A (en) Insecticidal compositions comprising 2-(benzofuran-7-yl)-hydrazinecarboxylic acid ester derivatives as active substance and process for preparing the active substances